Central Medical Library - Sofia

Patent protection policy of the therapeutic groups аngiotensin II receptor antagonists

Show simple item record

dc.contributor.author Manova, M.
dc.contributor.author Stoimenova, A.
dc.contributor.author Peikova, L.
dc.contributor.author Peikov, P.
dc.contributor.author Petrova, G.
dc.date.accessioned 2014-01-13T13:55:41Z
dc.date.available 2014-01-13T13:55:41Z
dc.date.issued 2012-04
dc.identifier.citation M. Manova, A. Stoimenova, L. Peikova, P. Peikov and G. Petrova. Patent protection policy of the therapeutic groups аngiotensin II receptor antagonists - Acta medica bulgarica , 39, 2012, No 1, 9-18. en_US
dc.identifier.issn 0324-1750
dc.identifier.uri http://hdl.handle.net/10861/377
dc.description Address for correspondence: Assoc. Prof. Assena Stoimenova, Ph. D., MPH Faculty of Pharmacy Department of Social Pharmacy and Pharmacoeconomics Medical University – Sofia 2 Dunav str., 1000 Sofia, Bulgaria 02/92 36 589 tel. 02/ 987 9874 mobile: 0887 749 665 e-mail: assena_stoimenova@mail.bg en_US
dc.description.abstract The goal of the current study is to analyze the patent protection status of medical products included in the therapeutic class аngiotensin II receptor antagonists or sartans. The analysis covered the period 1995-2008. A three – step internet patent database search methodology was applied in searching EPO, Orange book and Patent watch. Applications were systematised per IPC code, territory, manufacturer and date of patent issuing. The patent activity depends on the time of expiration of the main patent. The highest number of patents granted for IPC class A61K is due to the fact that this class is related with the therapeutic possibility of the formulations. Per territory protection activity is similar in regard to the prefered countries and follows the market dynamics. For some of the products additional factors might play an important role. Our study shows that a variety of factors are infl uencing the patent protection policy, such as the time of discovery, product application, disease priority, technologies etc. It appears that the therapeutic competition is more important than the generic one related to establishment of patent profi le of particular INN. This is in contrast with the beliefs that the patent protection policy affects mainly generic companies. en_US
dc.language.iso other en_US
dc.publisher Централна медицинска библиотека, МУ София / Central Medical Library - MU Sofia en_US
dc.subject Angiotensin II receptor antagonists, patent protection, patent policy en_US
dc.title Patent protection policy of the therapeutic groups аngiotensin II receptor antagonists en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

  • Acta Medica Bulgarica
    Многопрофилно списание, излизащо само на английски език. Съдържа авторски статии от водещи български медицински специалисти, отразяващи върховите постижения на българската медицина наука и практика. Публикуват се материали, отразяващи резултати от експериментални проучвания, клиника и казуистика. Излиза 2 пъти годишно. ISSN:0324-1750

Show simple item record